Validation of the Alopecia Areata Patient Priority Outcomes Questionnaire in Adults and Adolescents with Alopecia Areata

November 2021 in “ Dermatology and Therapy ”

Kathleen W. Wyrwich, Randall Winnette, Randall H. Bender, Kavita Gandhi, Nicole Williams, Nimanee Harris, Lauren Nelson

alopecia areata Alopecia Areata Patient Priority Outcomes AAPPO hair loss severity patient-reported outcomes AA

Studysummary This study found that the Alopecia Areata Patient Priority Outcomes questionnaire is a reliable and valid tool for measuring the severity and impact of hair loss in individuals with alopecia areata.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study validated the Alopecia Areata Patient Priority Outcomes (AAPPO) questionnaire as a reliable and valid tool for assessing hair loss severity and its impact on individuals with alopecia areata (AA). This disease-specific measure was tested in both adults and adolescents, providing a standardized method to evaluate the condition's effects. The validation of the AAPPO questionnaire helped in understanding the patient-reported outcomes, which are crucial for both clinical assessments and therapeutic interventions in AA.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

7 / 7 results

Quality of Life Measurement in Alopecia Areata: Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient-Oriented Outcomes

research Quality of Life Measurement in Alopecia Areata: Position Statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient-Oriented Outcomes

24 citations , June 2021 in “Journal of the European Academy of Dermatology and Venereology”

This review highlights current knowledge about quality of life assessment in alopecia areata, noting limited use of existing instruments and a need for further validation.

research Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study

11 citations , March 2021 in “Dermatology and therapy”

This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.

research A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States

63 citations , March 2020 in “Clinical Cosmetic and Investigational Dermatology”

This study suggests that the prevalence of alopecia areata in the US remains similar to high estimates from the 1970s, with significant implications for quality of life.

research Mechanisms of Tolerance and Potential Therapeutic Interventions in Alopecia Areata

12 citations , May 2017 in “Pharmacology & therapeutics”

This review discusses the mechanisms underlying immune tolerance failure in alopecia areata and highlights potential therapeutic avenues for restoring hair growth and achieving sustained remission, but reports no new clinical results.

research Alopecia Areata Update

391 citations , January 2010 in “Journal of The American Academy of Dermatology”

This article reviews the clinical presentation and histopathologic features of alopecia areata and proposes a hypothesis for its development, but it reports no new clinical results.

research Psychological Effects of Androgenetic Alopecia on Women: Comparisons with Balding Men and Female Control Subjects

222 citations , October 1993 in “Journal of The American Academy of Dermatology”

This study found that androgenetic alopecia causes significant psychological distress, particularly in women, who exhibit a more negative body image and less adaptive functioning compared to controls.

research The Psychological Effects of Androgenetic Alopecia in Men

192 citations , June 1992 in “Journal of The American Academy of Dermatology”

Hair loss can cause low self-esteem, anxiety, and depression in men.